-
An AI-Enhanced Targeted Literature Review Workflow to Support Inclusive Research Practices and Population Science Research: A Human-in-the-Loop Approach
Sep 9, 2025, 16:22 PM -
Estimating the Clinical and Economic Value of Aztreonam-Avibactam for the Treatment of Metallo-Beta-Lactamase–Producing Carbapenem- Resistant Enterobacterales Infections in China: Adopting the STEDI Value Framework
Sep 9, 2025, 16:22 PM -
Delayed Access to Diabetes Technology in Children With Migration Background: A Cross-Sectional Study on Treatment Equity in Austria
Sep 9, 2025, 16:22 PM -
Prevalence of Migraine in India: A Meta-Analysis With Subgroup Analyses by Population Type
Sep 9, 2025, 16:22 PM -
Real-World Differences in Breast Cancer Management by Detection Method: A Czech National Analysis
Sep 9, 2025, 16:22 PM -
NICE Technology Appraisal Submissions for Non-Small Cell Lung Cancer: Analysis and Insights
Sep 9, 2025, 16:22 PM -
Expert Consensus on a Definition for Children With Medical Complexity in England: A Modified Delphi Panel
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Perioperative Pembrolizumab for Early Stage Non-Small Cell Lung Cancer (NSCLC) in Greece
Sep 9, 2025, 16:22 PM -
Prediabetes Prevalence and Progression in the UAE: Insights for Early Intervention and Resource Optimization
Sep 9, 2025, 16:22 PM -
Real-World Evidence in Action: Assessing Drug-Drug Interactions to Drive Value-Based Decisions
Sep 9, 2025, 16:22 PM -
The Rise of Optimization in NICE Guidance: A Two-Decade Review With a Focus on Prevention
Sep 9, 2025, 16:22 PM -
Foregone Net Monetary Benefit From Underdiagnosis and Undertreatment of Mild Cognitive Impairment Due to Alzheimer’s Disease in the Medicare Population
Sep 9, 2025, 16:22 PM -
Patient-Centered Hearing Technology Assessment: Integrating ICF Into Multicriteria Decision Making
Sep 9, 2025, 16:22 PM -
Analysis and Characterization of Variations in Conceptual and Operational Definitions for GLP-1 Agonist Treatment Eligibility for Weight Management
Sep 9, 2025, 16:22 PM -
Variations in Screening and Medication Takeup Rates for Alzheimer’s Disease
Sep 9, 2025, 16:22 PM -
A Budget Impact Analysis of Switching From Von Willebrand Factor/Factor VIII Plasma-Derived Concentrate With 2.4-1 Ratio to the Concentrate With 1-1 Ratio for the Management of Von Willebrand Disease in Qatar
Sep 9, 2025, 16:22 PM -
Factors Associated With the Publication of Real-World Evidence Studies in Lung Cancer by Journal Impact Factor
Sep 9, 2025, 16:22 PM -
Mapping Access Pathways for New Medicines in Finland: A Real-World Review of HTA and Reimbursement Decisions
Sep 9, 2025, 16:22 PM -
Patient Perspectives on Mild-Moderate Infection Burden in Multiple Myeloma and Chronic Lymphocytic/Small Lymphocytic Leukemia
Sep 9, 2025, 16:22 PM -
Divergent Biologic Price Archetypes: Year-on-Year List Price Evolution Pre- and Post-Biosimilar Entry in the US, Europe, and Japan
Sep 9, 2025, 16:22 PM
